Novel PDZ binding kinase (PBK) inhibitor.

Novel PDZ binding kinase (PBK) inhibitor.

NP-118809 is a N-type calcium channel blocker.

NP161 is a potent and selective inhibitor of extracellular TRX (Thioredoxin 1) in vitro with IC50 of 0.54 uM.

NPD13668 (NPD-13668) is a chemical novel modulator of EZH2-mediated gene silencing, inhibits EZH2/PCR2 activity and decreases H3K27me3 levels.

NPD8733 (NPD-8733) is a small-molecule ligand of valosin-containing protein (VCP)/p97, binds to the D1 domain of VCP/p97.

NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.

NPT200-11 is an orally bioavailable and brain penetrating alpha-synuclein (ASYN) misfolding and aggregation inhibitor.

Nrf2 acticatior AI-1 is a small-molecule inducer of the antioxidant response element (ARE) that activates and stabilizes Nrf2 by covalently modifying Keap1, activates an ARE-dependent luciferase reporter with an EC50 of 2.7 uM.

Nrf2 acticatior AI-2 is a small-molecule inducer of the antioxidant response element (ARE) that activates and stabilizes Nrf2 by covalently modifying Keap1.

Nrf2 activator 16 is a potent Keap1-Nrf2 and Keap1-p-p62 protein-protein interaction inhibitor with IC50 of 0.91 uM and 1.8 uM respectively.

NRF2 inhibitor AEM1 is a specific small molecule inhibitor of Nrf2 transcriptional activity in cancer cells, shows no activity against a panel of >100 kinases (including isoforms of PI3K, AKT, and PKC).

NRX-103094 is an enhancer of an E3 ligase-substrate interaction.

NRX-103095 is an enhancer of an E3 ligase-substrate interaction.

NRX-1532 is an enhancer of an E3 ligase-substrate interaction.

NRX-1933 is an enhancer of an E3 ligase-substrate interaction.

NRX-252114 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCFβ-TrCP. NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. NRX-252114 induces mutant β-catenin degradation.

NRX-252262 is an enhancer of an E3 ligase-substrate interaction.

NRX-2663 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCFβ-TrCP. NRX-2663 enhances the binding of β-catenin peptide for β-TrCP with an EC50 of 22.9 µM and a Kd of 54.8 nM[1].

NS 9283 is a positive allosteric modulator of α4β2 receptor; increases the potency of Ach-evoked currents ~60 fold without effecting the maximum efficacy (HEK293-hα4β2 cells).

NS-018 (NS018, Ilginatinib) is a potent and highly selective JAK2 inhibitor (IC50=0.72 nM).

NS-018 hydrochloride (NS018, Ilginatinib) is a potent and highly selective JAK2 inhibitor (IC50=0.72 nM).

NS-018 maleate (NS018, Ilginatinib) is a potent and highly selective JAK2 inhibitor (IC50=0.72 nM).

NS-062 (NS062) is a novel, specific targeted covalent inhibitor that shows high reactivity toward Cys797 of EGFR.

NS-3-008 hydrochloride is a novel small-molecule transcriptional inhibitor of G0s2 (G0/G1 switch 2) with IC50 of 2.25 uM.

NS-3-008 is a novel small-molecule transcriptional inhibitor of G0s2 (G0/G1 switch 2) with IC50 of 2.25 uM.

NS-304(Selexipag; ACT-293987) is an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.

NSC 145366 is a novel, allosteric Hsp90 CTD (C-terminal domain) inhibitor, exhibits anti-proliferative activity in tumor cell lines with GI50 of 0.2-1.9 uM.

NSC 146109 is an activator of the tumor suppressor p53 that increases expression of p53 and the p53 target DR5 in wild-type and p53-knockout HCT116 colon adenocarcinoma cells.

NSC 146268 (NSC146268, 6-Aza-2-thiouridine) is a novel small molecule inhibitor of CD151, inhibits proliferation of metastatic triple negative breast cancer cell lines (MDA-MB 231 and MDA-MB 468, IC50 of 6.0 and 6.2 ug/mL).

NSC 15765 (Compound C5, DNA2 inhibitor C5) is an effective, selective and competitive inhibitor of DNA2 nuclease with IC50 of 20 uM.

NSC 191412 is a bioactive compound.

NSC 19630 (MIRA-1) is a potent, selective Werner syndrome helicase (WRN helicase) with IC50 of 20 uM.

NSC 23925 is a small molecule compound that reverses multiple drug resistance (MDR) in human cancer cell lines, reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR.

NSC 23925B is a small molecule agent that reverses MDR in cancer cells, reverses MDR in several drug-resistant cell lines expressing Pgp.

NSC 247030 is a bioactive chemical.

NSC 306711 (Ferristatin, NSC306711) is a small-molecule iron transport inhibitor that promotes degradation of the transferrin receptor independent of clathrin and dynamin, is sensitive to the cholesterol-depleting agents filipin and nystatin..

NSC 311068 is a small molecule that directly tragets and inhibits STAT3/5, significantly and selectively suppresses the viability of AML cells with high level of TET1 expression both in vitro and in vivo.

NSC 368262 is a selective STAT3 inhibitor that alkylates Cys468 in Stat3, blocks the DNA-binding activity of phosphorylated Stat3 homodimers with IC50 of 10-50 uM, without inhibiting the DNA-binding of phosphorylated Stat1 homodimers.

NSC 370284 is a small molecule that directly binds to and inhibits STAT3/5, significantly and selectively suppresses the viability of AML cells with high level of TET1 expression both in vitro and in vivo.

NSC 409012 is a bioactive chemical.

NSC 45576 is a potent Exchange proteins directly activated by cAMP (EPAC) inhibitor with IC50 of 1.7 uM.

NSC 6038 is a bioactive compound.

NSC 625987 is a potent, selective CDK4 inhibitor with IC50 of 0.2 uM, displays >500-fold selectivity over CDK2 (IC50 >100 uM for cdc2/cyclin A, cdk2/cyclin A and cdk2/cyclin E). .

NSC 630668 is a Hsc70 inhibitor that inhibits the endogenous and DnaJ-stimulated ATPase activity of hsc70.

NSC 65828 (NCI65828) is a small-molecule inhibitor of the ribonucleolytic activity of human angiogenin with Ki of 81 uM.

NSC 658497 is a small molecule inhibitor of Ras GEF, SOS1, binds to SOS1 with Kd of 7 uM but no H-Ras, competitively suppresses SOS1-Ras interaction, and dose-dependently inhibits SOS1 GEF activity.

NSC 663284 (SPS8I1;DA3003-1) is a potent inhibitor of the dual specificity protein phosphatase Cdc25 with Ki of 9/95//89 nM for Cdc25A/Cdc25B2/Cdc25C, displays 20- and 450-fold more selective over VHR or PTP1B phosphatases.

NSC 745887 is a small molecule that effectively inhibits the proliferation of various cancers by trapping DNA-topoisomerase cleavage, shows anticancer effects against human GBM cells via suppressing DcR3-associated signaling pathways.

NSC 80538 is a bioactive compound.

NSC112200 is a chemical inhibitor of the EZH2 deubiquitinase ZRANB1 (at 10 uM), destabilizes EZH2, promotes proteasomal degradation of EZH2 and inhibits the viability of TNBC cells.

NSC15364 is an inhibitor of Shiga Toxin.

NSC228155 is an activator of EGFR. It binds to the sEGFR dimerization domain II and modulates EGFR tyrosine phosphorylation.

NSC23005 is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.

NSC260594 (NSC 260594) is a specific inhibitor of HIV-1 RNA packaging, which involves preventing the interaction of Gag with SL3 by stabilizing this small RNA stem-loop which then leads to stabilization of the global packaging signal region (psi or ψ).

NSC348884 is a nucleolar phosphoprotein that displays several biological activities in ribosome biogenesis, cell proliferation, cytoplasmic/nuclear shuttle transportation, nucleic acid binding, ribonucleic cleavage, and centrosome duplication.

NSC49652 (NSC 49652) is a compound targeting the transmembrane domain (TMD) of death receptor p75NTR with IC50 of 10 uM in AraTM assays, alters the relative conformation of p75NTR TMDs and induces dynamic changes in the full-length receptor in mammalian c

NSC617145 is a Werner syndrome helicase (WRN) helicase inhibitor (IC50 = 250 nM).

NSC668394 (NSC 668394) is a small molecule inhibitor of ezrin, directly bind to ezrin with Kd of 12.59 uM.

NSC781406 is a highly potent PI3K and mTOR inhibitor with an IC50 of 2 nM for PI3Kα.

NSC-87877 is a cell-permeable inhibitor of both SHP-1 and SHP-2 with IC50 values of 355 and 318 nM respectively. It also inhibits EGF-induced Erk1/2 activation in HEK293 cells and significantly reduces MDA-MB-468 cell viability/proliferation.

NSI-189 is a nootropic and neurogenic research chemical derived from nicotinamide and pyrazine.

NTRC-844 (NTRC844) is a potent, selective neurotensin receptor type 2 (NTS2) with Ki of 23 nM, 100-fold selectivity over NTS1 receptor.

NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

NUC-1031(SP) is S form of NUC-1031 at P site.Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine.

NUC-3373 is a phosphoramidate-based prodrug of the monophosphate form of 5-fluoro-2'-deoxyuridine, the active metabolite of fluorouracil,an antimetabolite fluoropyrimidine analog of the pyrimidine nucleoside, with potential antineoplastic activity.

NUC-7738 is a phosphoramidate transformation of cordycepin (3’-deoxyadenosine; 3’-dA), a derivative of adenosine that was first isolated from Cordyceps sinensis.

Nuclear yellow (Hoechst S769121) exhibits excitation/emission maxima ~335/495 nm when bound to DNA.

NV01 is a small-molecule antagonist of the H3K9me3 binding to UHRF1 tandem tudor domain (TTD) with Kd of 5 uM..

NV03 is a small-molecule antagonist of the H3K9me3 binding to UHRF1 tandem tudor domain with Kd of 2.4 uM..

NVP DPP 728 is a potent and orally active inhibitor of dipeptidyl peptidase (DPP)-IV with Ki and IC50 values of 11 nM and 14 nM, respectively.

NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC50 of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC50 values of 0.584 µM, 0.7

NVP-231 is a potent, specific, and reversible CerK inhibitor(IC50=12±2 nM) that competitively inhibits binding of ceramide to CerK.

NVP-BGJ398 phosphate (Infigratinib phosphate, BGJ398 phosphate) is a potent, selective pan-FGFR inhibitor with IC50 of 0.9/1.0/1.4/60 nM for FGFR1/2/3/4, also shows high potenct against mutant FGFR3-K650E with IC50 of 4.9 nM.

NVP-BVU972 is a selective and potent Met inhibitor (IC50 = 14 nM). Antitumor agents.

NVP-CGM097 (CGM-097) is a potent and selective MDM2 inhibitor.

NVP-MELK8a hydrochloride (MELK8a hydrochloride) is a novel potent, and selective MELK inhibitor with IC50 of 2 nM.

NVP-QAV-572 is a potent PI3K kianse inhibitor with IC50 of 10 nM.

NVR 3-778 (NVR3-778, NVR 3778) is a small molecule inhibitor of HBV replication that targets the viral core protein, a first-in-class capsid assembly modulator.

NVS-CRF38 is a potent, selective, orally bioavailable corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50 of 70 nM..

NVS-PAK1-1 potently inhibits autophosphorylation of PAK1 (S144) at 0.25 µM in the Su86.86 cell line and MEK S289 phosphorylation with an IC50 = 0.21 in Su86.86 cells in which PAK2 is downregulated.

NXL101 is a novel quinoline bacterial DNA gyrase and topoisomerase IV inhibitor that shows potent activity against gram-positive bacteria, including methicillin- and fluoroquinolone-resistant strains.

NXY-059 (Cerovive) is an EGFR and HER2 autophosphorylation inhibitor, against purified EGFR and HER2 of 10.2 and 9.8 nM, respectively.

NY0116 (NY 0116) is a small molecule neuromedin U receptor 2 (NMUR2) with EC50 of 27.76 uM for hNMUR1 and 13.61 uM for hNMUR2 in intracellular calcium mobilization assays.

NY-0123 is a novel potent Exchange proteins directly activated by cAMP (EPAC) antagonist with IC50 of 0.9 and 2.4 uM for EPAC1 and EPAC2, respectively.

NY0128 (NY 0128) is a small molecule neuromedin U receptor 2 (NMUR2) with EC50 of 29.99 uM for hNMUR1 and 10.30 uM for hNMUR2 in intracellular calcium mobilization assays.

NY-0173 is a potent Exchange proteins directly activated by cAMP (EPAC) inhibitor with IC50 of 4.0 uM for EPAC1..

O-1602 (O1602) is an atypical cannabinoid, potent and selective agonist of GPR55 cannabinoid receptor with EC50 of 13 nM, shows no significant activity for CB1 and CB2 receptors (EC50>30 uM).

O304 is a novel AMPK activator.

OAC2 is an Oct4-activating compound which activates expression through the Oct4 gene promoter; enhances reprogramming efficiency by increasing the rate of production of induced pluripotent stem cells (iPSCs) from embryonic fibroblasts; an analog of OAC1.

OADS is a specific, reversible, small-molecule inhibitor directs against CLC (Chloride Channel) antiporter with Ki of 29 uM, has no specific effect on a CLC channel (ClC-1). .

OAT-1746 is a novel potent, selective, orally active inhibitors of Arginase 1 and 2 (ARG1/2) with IC50 of <50 nM.

OAT-177 is a potent, selective, orally active acidic mammalian chitinase (AMCase) inhibitor with IC50 of 14 and 19 nM against human and mouse AMCas, respectively, >150-fold selectivity over mCHIT1.

OAT-2068 is a potent, selective, orally bioavailable inhibitor of mouse chitotriosidase (mCHIT1) with IC50 of 29 nM, 143-fold selectivity over mAMCase.

OBA-09 is a simple ester of pyruvate and salicylic acid, main metabolites of pyruvate and aspirin, respectively, exerts robust neuroprotective effect in the postischemic brain in vivo.

OBE022 is a potent, highly selective, orally active antagonist of the contractile PGF2α prostaglandin receptor with Kb of 5.9 nM, shows no activity for other human PG receptors subtypes.

Obicetrapib is a CETP inhibitor, on the elevation of high-density lipoprotein cholesterol (HDL-C) and reduction of low-density lipoprotein cholesterol (LDL-C), alone and in combination with statin therapy.

OBP-801 (YM 753;Spiruchostatin A) is a novel cyclic-peptide-based HDAC inhibitor with IC50 of 2 nM.

OC000459, a Potent, Selective, and Orally Active D Prostanoid Receptor 2 Antagonist.

Ochratoxin A demonstrates nephrotoxicity and teratogenesis in animals, and shows inhibition of bacterial, yeast, and liver FARSL (phenylalanyl-tRNA synthetases) competitive with phenylalanine.

Ochratoxin B(OTB) is a non-chlorinated analog of OTA that has cytotoxic effects on kidney and liver cells in vitro but only minor effects in vivo, due to its rapid metabolism and excretion.

Oclacitinib, also known as PF03394197, is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.

Octahydrocurcumin is a hydrogenated derivatives of curcumin; metabolite of curcumin.

Octopamine (OA), a biogenic monoamine structurally related to noradrenaline, acts as a neurohormone, a neuromodulator and a neurotransmitter in invertebrates.

Odalasvir (ACH-3102, JNJ-64289901) is a potent, second-generation HCV NS5A inhibitor in development for the treatment of hepatitis C..

ODM-203 (ODM203) is a potent, selective, dual inhibitor of FGFR and VEGFR tyrosine kinases with approximately equal potency towards recombinant FGFR1, 2, 3 and 4, as well as VEGFR1, 2 and 3 (IC50=5-35 nM).

ODQ (sGC inhibitor ODQ) is a potent, selective, irreversible inhibitor of sGC (soluble guanylyl cyclase).

Officinalisinin I is a steroidal saponin, isolated from Anemarrhena asphodeloides.

OGG1 inhibitor O8 is a potent, selective inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1) with IC50 of 0.22 uM, displays no significant activity against other DNA Glycosylases (NEIL1, NTH1, Fpg, IC50>50 uM)..

OGT inhibitor 4a (OSMI-4 active form) is a novel potent, selective O-linked N-acetylglucosamine transferase (OGT) inhibitor with Kd of 8 nM, the active form of OSMI-4..

OHM1 is a potent HIF1α mimic that binds to CH1 domain of p300/CBP with Kd of 500 nM, reduces the level of HIF1α transcriptional activity under hypoxia to that observed under normoxia at 20 uM in A549 cells.

Olanexidine is a monobiguanide compound with bactericidal activity.

Oleamide is an endogenous fatty acid amide which can be synthesized de novo in the mammalian nervous system, and has been detected in human plasma.

Oleuropein is an antioxidant polyphenol isolated from olive leaf.

Oliceridine hydrochloride (Olinvo, TRV130) is a potent, selective, and G protein biased μ opioid receptor (MOR) agonist with pEC50 of 8.1.

Olinone is a selective inhibitor for the BET BRD1 with Kd of 3.4/3.7/8.6 uM for BRD4-BrD1/BRD3-BrD1/BRD2-BrD1, respectively, shows high selectivity over BET BRD2 (Kd>300 uM).

Olopatadine Hydrochloride

Olumacostat glasaretil is a small molecule inhibitor of acetyl coenzyme A carboxylase (ACC).

Omadacycline is novel, aminomethyl tetracycline antibiotic being developed for the treatment of community-acquired bacterial infections.

Ombitasvir is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A).

Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors.

Omecamtivmecarbil (CK-1827452) is a specific cardiac myosinactivator and a clinical drug for left ventricular systolic heart failure.

Omeprazole(Prilosec) is a proton pump inhibitor used in the treatment of dyspepsia.

ON 146040 is a potent, dual PI3K/BCR-ABL inhibitor with IC50 of 14/20 nM for PI3Kα/δ , IC50 of 20 nM for BCR/ABL.

ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.

ON108110 (ON-108110, ON 108110) is a novel multi-kinase inhibitor of protein kinase CK2 (CK2α1/2, IC50=3/2 nM) as well as CDK4/6 (IC50=2-24 nM).

ON1231320 is a potent selective inhibitor of Polo like kinase 2 (PLK2).

ONC212, a fluorinated-ONC201 analogue, is a promising anti-cancer drug and also a selective agonist of GPR132.

Oncrasin 1 is a proapoptotic substance. Induces abnormal nuclear aggregation of PKCι and suppressing RNA transcription.

ONO-3080573 is a potent LPA1 inhibitor with IC50 of 11 nM..

ONO-6126 is a potent and selective PDE4 inhibitor for the treatment of bronchial asthma and allergic conjunctivitis..

ONO-9780307 is a potent LPA1 inhibitor with IC50 of 27 nM..

ONO-9910539 is a potent LPA1 inhibitor with IC50 of 22 nM..

ONO-DI 004 is a potent, selective EP1 agonist..

OPC-21268 is a vasopressin 1 receptor antagonist potentially for the treatment of heart failure and hypertension.

Opicapone(BIA 9-1067) is a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.

OR59402;NSC 48107 is a bioactive compound.

Org 42599 is a cell-permeant, allosterically binding, small-molecule agonist of luteinizing hormone (LH) receptor that rescues the folding and cell surface expression mutant mutant human LH receptors A593P and S616Y (EC50=70.8 nM)..

Org 42599 is a cell-permeant, allosterically binding, small-molecule agonist of luteinizing hormone (LH) receptor that rescues the folding and cell surface expression mutant mutant human LH receptors A593P and S616Y (EC50=70.8 nM)..

Orita-13 is potent inhibitor of Migration inhibitory factor (MIF) tautomerase activity with Ki of 17 uM..

Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria.

Oritavancin is a semisynthetic glycopeptide antibiotic that inhibits the growth of Gram-positive bacteria.

Orlistat is a drug designed to treat obesity. Orlistat's primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. Orlistat is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.

ORM-10962 is a potent, highly selective sodium-calcium exchanger (NCX) inhibitor, significantly reduces inward/outward NCX currents with IC50 of 55 and 67 nM, respectively.

Orotic acid (6-Carboxyuracil)

Orvepitant (GW823296) is a potent and selective, brain penetrant NK1 receptor antagonist with pKi of 10.2.

Oseltamivir acid (GS 4071, Ro 64-0802, Oseltamivir carboxylate) is a potent inhibitor of influenza neuraminidase (NA) with Ki of <1 nM for both A and B strains,showed potent activity against COVID-19(SARS-COV-2).

OSI-420 (Desmethyl Erlotinib,CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for human EGFR and EGFR autophosphorylation in tumor cells.

Osilodrostat is an inhibitor of aldosterone synthase and aromatase, for treating Cushing’s disease.

Osimertinib analogue (C-005) is a potent EGFR inhibitor, which is 2-5 fold more selective than Osimertinib between above EGFR mutants and wild-type EGFR(A431) cells.

OSMI-1 is a cell-permeable, small molecule O-GlcNAc transferase (OGT) inhibitor with IC50 of 2.7 uM.

OSMI-4 (OGT inhibitor 4b) is a novel potent, selective, cell-active O-linked N-acetylglucosamine transferase (OGT) inhibitor with EC50 of ~3 uM.

ILK-IN-2 (OSU-T315 analog) is a ILK inhibitor.

OSW-1 is a natural anti-enterovirus and anti-cancer compound that targets oxysterol-binding protein (OSBP) with Ki of 26 and 54 nM for OSBP and ORP4L, respectively.

Otilonium Bromide is an antimuscarinic used as a spasmolytic agent.

OTX008 is a selective inhibitor of galectin-1.

OTX-015 is a new potent BRD2/3/4 inhibitor with evident anti-proliferative activity in several cell lines representative of mature B-cell tumors.

OUP-16 is a potent H4R agonist with a considerable selectivity over H3R..

o-vanillin (C29L.

OX-14 is a highly potent farnesyl pyrophosphate synthase (FPPS) inhibitor with IC50 of 2.46 nM, with significantly lower binding affinity to hydroxyapatite.

Oxadiazon is a preemergent herbicide.

Oxamflatin is a potent inhibitor of histone deacetylases (IC50 = 15.7 nM).

Oxfendazole

Oxibendazole

Oxonic acid potassium salt is an inhibitor of uricase, oxonic inhibits the phosphorylation of 5-FU to 5-fluorouridine-5'-monophosphate catalyzed by pyrimidine phosphoribosyl-transferase in a different manner from allopurinol in cell-free extracts and inta

Oxybenzone is a benzophenone derivative used as a sunscreen agent.

Oxybutynin is also a possible treatment of hyperhidrosis (hyper-active sweating) .

Oxythiamine chloride is a small molecule transketolase inhibitor with Kd of 33 nM, shows functional assay of human transketolase inhibition in HCT-116 cells with EC50 of 26 nM.

Oxythiamine, an antimetabolite and a vitamin B1 antagonist, is a well-known thiamine antagonist and inhibitor of transketolase.

Ozagrel HCl

Ozagrel(OKY-046) sodium salt is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.

P005091(P5091) is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM.

P005672 is a phase II drug for antibacterial/anti-inflammatory acne treatment.

P053 (P-053, CerS1 inhibitor P053) is a potent, selective, orally active inhibitor of ceramide synthase 1 (CerS1) with IC50 of 0.5 uM, displays >10-fold selectivity for inhibition of CerS2, CerS4, CerS5, and CerS6.

P22077 is a potent inhibitor of ubiquitin-specific protease (USP) 7 (EC50=8.6 uM), P22077 also inhibits the closely related deubiquitinase (DUB) USP47.

p32 inhibitor M36 is a novel small molecule inhibitor of p32 mitochondrial protein, binds directly to p32 and inhibits p32 association with LyP-1.

p38 MAPK-IN-4 is a potent and selective inhibitor of p38 MAPK with IC50 of 68 nM for p38α, inhibits LPS-induced TNFα release in THP-1 cells with IC50 of 187 nM.

p38α inhibitor 1 is a p38α inhibitor extracted from patent WO 2008076265 A1.

p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC50 of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay.

P516-0475 is a novel chemical inducer of Streptococcus quorum sensing acts by inhibiting the pheromone-degrading endopeptidase PepO (IC50=10 uM).

P53R3 is a novel p53 reactivator that restores sequence-specific DNA binding of the endogenously expressed p53(R175H) and p53(R273H) mutants in gel-shift assays.

P62-mediated mitophagy inducer (PMI) is a small molecule P62-mediated mitophagy inducer that activates mitophagy without recruiting Parkin or collapsing membrane potential and retains activity in cells devoid of a fully functional PINK1/Parkin pathway.

P7C3-A20 is an analogue of P7C3，a proneurogenic, neuroprotective agent.

PAC1 (Compound PAC1) is a novel PROTAC antibody conjugate, more potent estrogen receptor-alpha (ERα) degrader compared to PROTAC without antibody conjugation..

PAC-1 is a potent procaspase-3 activator with EC50 of 0.22 μM and the first small molecule known to directly activate procaspase-3 to caspase-3.

PACAP (6-38), human, ovine, rat is a potent PACAP receptor antagonist with IC50s of 30, 600, and 40 nM for PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2, respectively.

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Pactamycin (NSC 52947) is a potent protein synthesis inhibitor, inhibits protein synthesis at the translocation step on the 70S ribosome, has activity against Gram-positive and Gram-negative bacteria, and broad antitumor, antiviral, and antiplasmodial act

Padsevonil (UCB-0942, UCB0942) is a potential anti-seizure agent that functions as a pre- and post-synaptic inhibitor..

PAFAH inhibitor P11 (P11) is a potent, selective platelet-activating factor acetylhydrolases PAFAH1b2 and PAFAH1b3 inhibitor with IC50 of 40 nM and 900 nM respectively.

Palifosfamide is a novel molecule for the treatment of sof tissue sarcoma.

Palmitelaidic acid is the trans isomer of palmitoleic acid. Palmitoleic acid is one of the most abundant fatty acids in serum and tissue.

Palmostatin B is a potent Acyl protein thioesterase 1 (APT1.

Palovarotene (R-667, RO-3300074) is a selective retinoic acid receptor gamma(RAR-γ) agonist for the treatment of emphysema.

Pamidronate Disodium

Pamidronic acid

Pamiparib (BGB-290, BGB290) is a highly potent, selective and brain penetrant PARP1/2 inhibitor with potent anti-tumor activity.

Panadiplon (U-78875) is an anxiolytic drug with a novel chemical structure that is not closely related to other drugs of this type.

Pandacostat is the first nonselective HDAC inhibitor (pan-HDACi) with Ki of 0.12/0.07/0.95/0.18/0.032/1.1/0.5/1.4 uM for HDAC1/2/3/4/5/6/7/8/9, respectively.

pan-PIM inhibitor 17 is a potent, selective, orally available inhibitor of Pim kinase with IC50 of 0.8, 5.1 and 1.8 nM for Pim1, 2 and 3, respectively.